FI4349369T3 - Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa - Google Patents

Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa

Info

Publication number
FI4349369T3
FI4349369T3 FIEP23209711.3T FI23209711T FI4349369T3 FI 4349369 T3 FI4349369 T3 FI 4349369T3 FI 23209711 T FI23209711 T FI 23209711T FI 4349369 T3 FI4349369 T3 FI 4349369T3
Authority
FI
Finland
Prior art keywords
pharmaceutically acceptable
acceptable salt
naltrexone
bupropion
pharmaceutical composition
Prior art date
Application number
FIEP23209711.3T
Other languages
English (en)
Finnish (fi)
Inventor
Shawn Flanagan
Eduardo Dunayevich
Original Assignee
Nalpropion Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4349369(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nalpropion Pharmaceuticals Llc filed Critical Nalpropion Pharmaceuticals Llc
Application granted granted Critical
Publication of FI4349369T3 publication Critical patent/FI4349369T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acoustics & Sound (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
FIEP23209711.3T 2010-12-03 2011-12-02 Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa FI4349369T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03

Publications (1)

Publication Number Publication Date
FI4349369T3 true FI4349369T3 (fi) 2025-12-17

Family

ID=46172304

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP23209711.3T FI4349369T3 (fi) 2010-12-03 2011-12-02 Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa
FIEP21152314.7T FI3884947T3 (fi) 2010-12-03 2011-12-02 Lääkkeen hyötyosuuden lisääminen naltreksonihoidossa

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP21152314.7T FI3884947T3 (fi) 2010-12-03 2011-12-02 Lääkkeen hyötyosuuden lisääminen naltreksonihoidossa

Country Status (27)

Country Link
US (1) US20130245056A1 (enExample)
EP (4) EP3222280B1 (enExample)
JP (5) JP6008866B2 (enExample)
KR (5) KR102258043B1 (enExample)
CN (1) CN103313711A (enExample)
AR (2) AR093182A1 (enExample)
AU (2) AU2011336304B2 (enExample)
BR (1) BR112013013390A2 (enExample)
CA (2) CA3239386A1 (enExample)
CL (1) CL2013001564A1 (enExample)
CY (2) CY1118968T1 (enExample)
DK (3) DK3884947T3 (enExample)
ES (2) ES2625527T3 (enExample)
FI (2) FI4349369T3 (enExample)
HR (3) HRP20240115T1 (enExample)
HU (3) HUE034393T2 (enExample)
IL (3) IL226504B (enExample)
LT (3) LT2646031T (enExample)
MX (2) MX356801B (enExample)
PL (3) PL3222280T3 (enExample)
PT (3) PT3222280T (enExample)
RS (3) RS65198B1 (enExample)
RU (1) RU2640561C2 (enExample)
SI (3) SI3884947T1 (enExample)
SM (3) SMT202100227T1 (enExample)
TW (1) TWI618536B (enExample)
WO (1) WO2012075459A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
JP6008866B2 (ja) * 2010-12-03 2016-10-19 オレキシジェン・セラピューティクス・インコーポレーテッド ナルトレキソン療法における薬物バイオアベイラビリティの増加
IL300868A (en) 2012-06-06 2023-04-01 Orexigen Therapeutics Inc Methods for treating overweight and obesity
EP3253379A4 (en) * 2015-02-07 2018-10-10 Intas Pharmaceuticals Limited Pharmaceutical composition for the treatment of obesity
KR20200072445A (ko) * 2017-03-28 2020-06-22 엘디엔 파마 리미티드 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
PT2316456T (pt) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
AU2006275914A1 (en) 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
AR058239A1 (es) 2005-11-28 2008-01-23 Orexigen Therapeutics Inc Metodos para tratar trastornos de ansiedad
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
PT2484346T (pt) * 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
KR101264789B1 (ko) * 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
CA2693992C (en) * 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20080110792A1 (en) * 2006-11-09 2008-05-15 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
KR101971218B1 (ko) * 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
ES2906582T3 (es) * 2007-04-11 2022-04-19 Biomarin Pharm Inc Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
JP6008866B2 (ja) * 2010-12-03 2016-10-19 オレキシジェン・セラピューティクス・インコーポレーテッド ナルトレキソン療法における薬物バイオアベイラビリティの増加

Also Published As

Publication number Publication date
SMT202100227T1 (it) 2021-07-12
CN103313711A (zh) 2013-09-18
KR20140035320A (ko) 2014-03-21
IL279626A (en) 2021-03-01
RS62149B1 (sr) 2021-08-31
JP6008866B2 (ja) 2016-10-19
RU2017144631A (ru) 2019-02-18
KR20200044158A (ko) 2020-04-28
SI3222280T1 (sl) 2021-11-30
HUE053831T2 (hu) 2021-07-28
RU2017144631A3 (enExample) 2021-04-13
IL270841A (en) 2020-01-30
AR124500A2 (es) 2023-04-05
AR093182A1 (es) 2015-05-27
RU2013127423A (ru) 2015-01-10
PL3884947T3 (pl) 2024-05-06
JP6456890B2 (ja) 2019-01-23
JP2013544290A (ja) 2013-12-12
CL2013001564A1 (es) 2014-05-02
EP4349369A2 (en) 2024-04-10
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
LT3884947T (lt) 2024-03-12
PT3222280T (pt) 2021-04-22
EP4349369A3 (en) 2024-05-15
EP2646031A1 (en) 2013-10-09
MX384662B (es) 2025-03-14
AU2011336304A1 (en) 2013-07-11
EP4349369B1 (en) 2025-09-17
SMT201700232T1 (it) 2017-07-18
KR102105857B1 (ko) 2020-05-04
IL226504B (en) 2021-01-31
RS65198B1 (sr) 2024-03-29
TWI618536B (zh) 2018-03-21
HRP20210618T1 (hr) 2021-09-17
AU2017204309A1 (en) 2017-07-13
FI3884947T3 (fi) 2024-01-30
KR20180069089A (ko) 2018-06-22
KR20210063473A (ko) 2021-06-01
PT2646031T (pt) 2017-05-25
DK2646031T3 (en) 2017-05-22
CA3239386A1 (en) 2012-06-07
LT2646031T (lt) 2017-06-26
ES2625527T9 (es) 2018-09-25
US20130245056A1 (en) 2013-09-19
KR101984500B1 (ko) 2019-05-31
JP2022060331A (ja) 2022-04-14
CA2819262C (en) 2024-05-28
HRP20170734T1 (hr) 2017-08-11
EP3222280A1 (en) 2017-09-27
SI3884947T1 (sl) 2024-06-28
MX2013006071A (es) 2013-10-01
JP2024071605A (ja) 2024-05-24
EP2646031B9 (en) 2018-01-10
EP3884947B1 (en) 2023-11-15
JP2019056004A (ja) 2019-04-11
HUE034393T2 (en) 2018-02-28
DK3222280T3 (da) 2021-04-19
HUE065852T2 (hu) 2024-06-28
EP3222280B1 (en) 2021-01-20
HRP20240115T1 (hr) 2024-06-07
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
CY1118968T1 (el) 2018-01-10
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
PL3222280T3 (pl) 2021-11-29
ES2866879T3 (es) 2021-10-20
JP7025319B2 (ja) 2022-02-24
ES2625527T3 (es) 2017-07-19
AU2011336304B2 (en) 2017-03-30
CY1124331T1 (el) 2022-07-22
RU2640561C2 (ru) 2018-01-09
SMT202400038T1 (it) 2024-03-13
EP3884947A1 (en) 2021-09-29
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
EP2646031A4 (en) 2014-04-23
MX356801B (es) 2018-06-13
PT3884947T (pt) 2024-02-16
JP2016210809A (ja) 2016-12-15
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
LT3222280T (lt) 2021-05-10
KR20190058702A (ko) 2019-05-29
TW201304780A (zh) 2013-02-01

Similar Documents

Publication Publication Date Title
FI4349369T3 (fi) Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa
AU2023200826B2 (en) Administration of berberine metabolites
JP6446552B2 (ja) 体重と体脂肪減少に用いられる組成物およびその医薬品と使用
JP2013544290A5 (enExample)
JP2014528474A5 (enExample)
JP2015515475A5 (enExample)
JP2010525050A5 (enExample)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2013516493A5 (enExample)
HRP20170003T1 (hr) Uporaba inhibitora aromataze za liječenje hipogenadizma i srodnih bolesti
JP2011510922A5 (enExample)
JP2016505050A5 (enExample)
WO2011126342A3 (ko) 대잎둥굴레 또는 층층갈고리둥굴레 추출물의 신규한 용도
RU2013129518A (ru) Профилактика или лечение избыточной массы и ожирения у пациентов с диабетом 2 типа
JP2013540133A5 (enExample)
JP2013511287A5 (enExample)
WO2018093237A3 (ko) 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물
UA108980C2 (en) APPLICATION OF DONEDARONE FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS
RU2014146562A (ru) Композиция, содержащая альфа-липоевую кислоту и гонокиол, для лечения нейропатий
RU2009145804A (ru) Аксомадол для лечения боли от артроза
WO2010007085A3 (en) Use of gcn5 inhibitors in medicine
KR20190134671A (ko) 체중을 감소시키고 체지방을 감소시키기 위한 조성물 및 그의 제약 생성물 및 적용
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물